PR 92988 

MILAN, November 11, 2021, /PRNewswire=KYODO JBN/--

Hovione, the global leader in spray drying and particle engineering, today

announced that it is expanding its industrial facilities around the world to

support its ambitious growth objectives. The company has been on an expansion

track since 2016 in Portugal, Ireland and New Jersey with the aim of continuing

to increase its capacity and capabilities to address customer needs.

The announcement of a $170 million investment in Hovione units in Portugal,

Ireland, and New Jersey, leading to a global capacity increase of approximately

25%, was made at CPhI Wordwide, in Milan, by Guy Villax, CEO, and Jean-Luc

Herbeaux, COO.  

These investments will be used to support growth in the company´s pharma custom

development and manufacturing service business, fueled by strongly growing

demand for Hovione´s integrated and differentiated services in drug substance

manufacturing, particle engineering and most recently drug product

manufacturing.  The expansion will go hand-in-hand with a build-up of Hovione´s

global team with the creation of more than 300 new jobs globally. This strategy

will allow the company to continue to address difficult-to-meet client needs

while reinforcing its commitment to the Hovione values and standard of quality.

In the USA, Hovione will add a 2900m2 building next to its current facility in

East Windsor, New Jersey, laying the foundations for a state-of-the-art Hovione

Campus. The upcoming cycle of investment will bring additional commercial spray

drying capacity online by 2023. Further investments will follow with the aim to

solidify the company´s integrated offer: API - Particle - Drug Product in the

region.  This expansion will allow Hovione to accompany existing and new

customers favoring US-based manufacturing through their development cycles all

the way to commercial.

The capacity and capabilities of Hovione´s Cork site in the Republic of Ireland

will also be upgraded to enable the production of Highly Potent Active

Pharmaceutical Ingredients (HPAPI) and to facilitate onboarding of Drug

Substance Manufacturing projects of all sizes.  The investment will create an

ecosystem in which large customer projects with unique technologies can find a

home by connecting to the existing infrastructure and equipment. The site will

also receive a new commercial size spray dryer to support the growing demand

for particle engineering services.  

In Portugal, Hovione is ready to start operations of its most recent facility

with an increase in chemical synthesis capacity for High Potency Active

Pharmaceutical Ingredients (HPAPI). The building is also prepared to receive a

new commercial spray dryer to respond to the future needs of the global drug

market.

"Hovione is in it for life and what better way to manifest this than through

expansion of our global capacity and capabilities. Our sustainable organic

growth strategy will allow us to keep true to those values that have been

guiding us for more than 60 years", says Guy Villax, Chief Executive Officer.

"These investments reinforce our integrated specialized offer globally,

providing our clients with a line of sight for their projects.  Focus is placed

on facilitating and speeding up the drug development cycle and launch, by

providing API manufacturing, Particle Engineering and Tableting services in

each site.  Our strategy continues to be to grow organically via investments in

our existing sites, which are designed for purpose.  This reduces the

complexity associated with the growth journey and allows us to focus our

management attention on what counts most, i.e. guaranteeing that our clients go

to market with quality, safe and effective medicines for their patients" says

Jean-Luc Herbeaux, Hovione's Chief Operation Officer.

About Hovione

Hovione(https://www.hovione.com/) is an international company with over 60

years of experience as a Contract Development and Manufacturing Organization

(CDMO) and is currently a fully integrated supplier offering services for drug

substance, drug product intermediate and drug product. With four FDA inspected

sites(https://www.hovione.com/hovione-worldwide) in the USA, China, Ireland and

Portugal and development laboratories in Lisbon, Portugal and New Jersey, USA,

the company provides branded pharmaceutical customers services for the

development and compliant

manufacture(https://www.hovione.com/products-and-services/contract-manufacturing

-services/particle-engineering) of innovative drugs including highly potent

compounds. For generic pharmaceutical customers the company offers niche API

products. Hovione also provides proprietary product development and licensing

opportunities for drug

products(https://www.hovione.com/products-and-services/contract-manufacturing-se

rvices/drug-product/drug-product-development. In the inhalation area, Hovione

is the only independent company offering a complete range of services.  

Isabel Pina, ipina@hovione.com, Tel.: 0035121 982 9362

Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg

SOURCE: Hovione